FDA's Bulks List: Section 503A FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding Restore Health Consulting This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved The reason peptide access is changing comes down to two regulatory categories most patients don't know exist: 503A and 503B. 503A = traditional compounding pharmacies. State licensed, patient specific prescriptions. 503B = FDA registered outsourcing